Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTEND: Melagatran/Ximelagatran vs Enoxaparin for VTE Prevention in Hip Surgery
NCT00206089Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 16
01
Overview
A Phase 3 trial of ximelagatran in venous thromboembolism (VTE), sponsored by AstraZeneca. Started Sep 2005; status: terminated.
02
Drugs
ximelagatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00206089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206089.